Zacks: ObsEva SA (OBSV) Given Average Recommendation of “Strong Buy” by Analysts
ObsEva SA (NASDAQ:OBSV) has been given an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.
Brokerages have set a one year consensus price target of $24.00 for the company and are expecting that the company will post ($0.48) EPS for the current quarter, according to Zacks. Zacks has also assigned ObsEva SA an industry rank of 113 out of 265 based on the ratings given to related companies.
OBSV has been the subject of several analyst reports. Credit Suisse Group reissued an “outperform” rating and issued a $27.00 target price on shares of ObsEva SA in a research note on Tuesday, April 18th. Zacks Investment Research raised shares of ObsEva SA from a “sell” rating to a “hold” rating in a research note on Tuesday, May 30th. Finally, HC Wainwright initiated coverage on shares of ObsEva SA in a research note on Thursday, June 29th. They issued a “buy” rating and a $27.00 target price for the company.
Shares of ObsEva SA (NASDAQ:OBSV) traded down 2.30% during midday trading on Friday, hitting $7.63. 5,801 shares of the stock were exchanged. The firm’s market cap is $203.13 million. ObsEva SA has a 12-month low of $5.00 and a 12-month high of $14.69. The firm has a 50-day moving average price of $7.85 and a 200 day moving average price of $9.18.
ObsEva SA (NASDAQ:OBSV) last announced its earnings results on Thursday, May 18th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.17. Analysts predict that ObsEva SA will post ($2.04) earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Baker Avenue Asset Management LP bought a new position in ObsEva SA during the first quarter worth approximately $104,000. Paloma Partners Management Co bought a new position in ObsEva SA during the first quarter worth approximately $131,000. Sphera Funds Management LTD. increased its position in ObsEva SA by 9.7% in the second quarter. Sphera Funds Management LTD. now owns 231,497 shares of the company’s stock worth $1,979,000 after buying an additional 20,411 shares in the last quarter. Iguana Healthcare Management LLC bought a new position in ObsEva SA during the first quarter worth approximately $260,000. Finally, Spark Investment Management LLC bought a new position in ObsEva SA during the first quarter worth approximately $518,000. 49.11% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/13/zacks-obseva-sa-obsv-given-average-recommendation-of-strong-buy-by-analysts.html.
ObsEva SA Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.